NASDAQ:VCNXVaccinex Stock Price, Forecast & News

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VCNX stock has increased by 43.2% and is now trading at $5.97.
View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaccinex.

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Vaccinex.

Vaccinex Inc (NASDAQ:VCNX) posted its earnings results on Thursday, May, 14th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.30.
View Vaccinex's earnings history.

1 equities research analysts have issued 1-year target prices for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 268.5% from the stock's current price.
View analysts' price targets for Vaccinex.

Media headlines about VCNX stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vaccinex earned a daily sentiment score of -4.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Vaccinex.

Vaccinex saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 29,000 shares, a drop of 85.4% from the June 30th total of 199,300 shares. Based on an average trading volume of 508,900 shares, the short-interest ratio is presently 0.1 days. Currently, 0.8% of the shares of the company are short sold.
View Vaccinex's Short Interest.

Some companies that are related to Vaccinex include Ovid Therapeutics (OVID), Zafgen (ZFGN), Xenon Pharmaceuticals (XENE), Kamada (KMDA), Merus (MRUS), Atreca (BCEL), ANI Pharmaceuticals (ANIP), Albireo Pharma (ALBO), Axovant Sciences (AXON), MannKind (MNKD), AMAG Pharmaceuticals (AMAG), Progenics Pharmaceuticals (PGNX), Seres Therapeutics (MCRB), Passage Bio (IMRA) and CytomX Therapeutics (CTMX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

(VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCNX stock can currently be purchased for approximately $5.97.

Vaccinex has a market capitalization of $99.40 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]